Abeona Therapeutics Inc

In a Stage 2 advance with clear higher highs and higher lows, price has broken above a key pivot but is currently extended and overbought. Speculative engagement should be deferred until a pullback into the rising EMA 9/21/50 cluster confirms support.

• ↑Q1 net product revenue was $8.7 M, +262.5% YoY, indicating strong ZivaSkin traction
• ↑Forecasts include 40.5% annual revenue growth and 32.9% EPS growth
• ↓Q1 net loss reached $17.1 M vs $12 M a year ago, pressuring cash burn